Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Progyny (PGNY) stocks

Learn how to easily invest in Progyny stocks.

Progyny Inc
+ $0.69 ( + 1.56%)

Progyny (PGNY) is a leading health information services business based in the US. It opened the day at $59.85 after a previous close of $59.55. During the day the price has varied from a low of $59.25 to a high of $61.96. The latest price was $61.93 (25 minute delay). Progyny is listed on the NASDAQ and employs 311 staff. All prices are listed in US Dollars.

How to buy stocks in Progyny

  1. Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PGNY – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Progyny stock price (NASDAQ:PGNY)

Use our graph to track the performance of PGNY stocks over time.

Progyny shares at a glance

Information last updated 2021-06-28.
Previous close$59.55
Change $2.38
Change % 3.9966%
Volume 1,071,076
Information last updated 2022-08-13.
52-week range$25.67 - $68.32
50-day moving average $31.59
200-day moving average $42.00
Wall St. target price$62.50
PE ratio 90.02
Dividend yield $0 (0%)
Earnings per share (TTM) $0.50

Compare stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 5 of 5
Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
CIBC Investor's Edge
Finder Rating:
4 / 5
$0 if conditions met, else $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Young investors 18 to 24 can get free online trades and a $0 annual account fee. Conditions apply.
Interactive Brokers
Finder Rating:
4.1 / 5
min $1.00, max 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Finder Rating:
3.9 / 5
Stocks, ETFs
Get $25 when you open a Wealthsimple account and fund at least $150.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get almost $500 in commission free trades when you fund your new account with a minimum of $10,000. Conditions apply. Ends August 31, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Progyny stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Progyny price performance over time

Historical closes compared with the close of $61.93 from 2022-08-12

1 week (2022-08-05) 50.50%
1 month (2022-07-14) 113.99%
3 months (2022-05-11) 87.33%
6 months (2022-02-10) N/A
1 year (2021-08-13) 34.25%
2 years (2020-08-14) 108.80%
3 years (2019-08-10) N/A
5 years (2017-08-10) N/A

Is Progyny under- or over-valued?

Valuing Progyny stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Progyny's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Progyny's P/E ratio

Progyny's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 90x. In other words, Progyny shares trade at around 90x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Progyny's EBITDA

Progyny's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $19 million.

The EBITDA is a measure of a Progyny's overall financial performance and is widely used to measure a its profitability.

Progyny financials

Revenue TTM $617.1 million
Operating margin TTM 2.86%
Gross profit TTM $112.1 million
Return on assets TTM 2.85%
Return on equity TTM 17.7%
Profit margin 7.39%
Book value $3.38
Market capitalisation $4.1 billion

TTM: trailing 12 months

Progyny share dividends

We're not expecting Progyny to pay a dividend over the next 12 months.

Progyny share price volatility

Over the last 12 months, Progyny's shares have ranged in value from as little as $25.67 up to $68.32. A popular way to gauge a stock's volatility is its "beta".

PGNY.US volatility(beta: 1.85)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Progyny's is 1.85. This would suggest that Progyny's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Progyny overview

Progyny, Inc. , a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site